Wavefront Therapeutics is a preclinical biotech focused on addressing areas of high unmet need in myocardial ischemia. By targeting novel biology, Wavefront has developed intra-cellularly targeted peptides that provide first in disease treatments for cardiac arrest and reperfusion injury, with validation through porcine models. With our lead asset completing lead-optimization work in 2026, we anticipate launching first in human trials in 2028 with potential for commercial launch in 2031.

Wavefront’s three peptides related to the treatment of acute manifestations of myocardial ischemia are the following

A) Peptide A-301 is administered with epinephrine as part of advanced cardiac life support as part of the treatment of a cardiac arrest to increase survival and provide neuroprotective benefits.

B) Peptides from our second program (B-201 and B-301) are administered during a primary percutaneous coronary intervention for a ST-elevation myocardial infarction as a means of preventing ischemic reperfusion injury.